While this article pertains to an obesity drug and exceptional demand, I thought that we might try to keep things like this in our memory banks, if we think that things might work out kinda similar to Wegovy's "problem" of having a good thing.

Consider it some weekend reading, or just take a break and get to it next week. Enjoy your weekend!

PHARMACEUTICALS

Novo Nordisk cuts some U.S. supply of Wegovy obesity drug as demand soars

KEY POINTS

• Novo Nordisk said Thursday it was cutting the supply of starter doses of its obesity drug Wegovy in the U.S. as it struggles to keep up with surging demand.
• Chief Financial Officer Karsten Munk Knudsen told CNBC that the plans were intended “to safeguard continuity of care” for existing patients in the U.S. market.
• Novo Nordisk reported forecast-beating first-quarter sales Thursday, however shares were down 7% in early deals.

Pharmaceuticals Pharmaceuticals